Lindsey Tanner, AP Nearly one in 20 Americans older than 50 have artificial knees, or more than four million people, according to the first national estimate showing how common these replacement joints have become in an aging population. Doctors know the number of knee replacement operations has surged in the past decade, especially in baby boomers.
/PRNewswire-USNewswire/ -- In a first-ever national survey of orthopaedic surgeons, 96 percent said they have practiced defensive medicine - the ordering of tests, referrals to specialists and hospital admissions primarily to avoid liability and without significant benefit to patients - according to a new study presented today at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).
/PRNewswire/ -- Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, today announced the results of a new study for its BIRMINGHAM HIPT Resurfacing (BHR) System. The study, carried out at the request of the FDA, followed the progress of the first 400 BHR patients in the United Kingdom and found that after 10 years, 99% were either satisfied or extremely satisfied with their BHR procedure.
/PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced preliminary results today from a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.
/PRNewswire-USNewswire/ -- New research presented at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found that more than 4.5 million Americans are living with a total knee replacement (TKR), as the number of TKR surgeries has more than doubled over the past decade, with the sharpest rise among younger patients.
Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in musculoskeletal health, and ISTO Technologies, Inc., an orthobiologics company focused on developing breakthrough products to regenerate and restore function to damaged cartilage and bone, today announced a Phase III clinical study to evaluate DeNovo ® ET Engineered Tissue Graft, an engineered cartilage implant intended to repair cartilage defects in the knee.
Two Los Angeles-area outpatient clinics affiliated with the 1-800 GET-THIN marketing company have temporarily stopped Lap-Band weight-loss surgeries while they conduct a review of the procedure. The move follows Irvine-based Allergan's announcement last week that it would stop selling the device to companies affiliated with the ad campaign.
/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the U.S. launch of the TruePathT CTO Device, designed to facilitate the crossing of chronic total occlusions (CTOs, or complete blockages) within the peripheral vasculature. The Company will begin marketing the product immediately in the U.
WASHINGTON, Pa. (AP) — A Pennsylvania woman who submitted nearly $100,000 worth of fake cancer treatment insurance claims for herself and her husband must repay the money while she serves nearly nine years on probation. Brown pleaded guilty in August to submitting the phony claims from August 2006 through May 2008.
/PRNewswire-USNewswire/ -- As the debate in Congress over reauthorizing the statute governing medical devices intensifies, Consumers Union is stepping up its campaign to strengthen the law to better protect patients from potential safety risks. This week, Consumers Union's Safe Patient Project is bringing eight patient safety activists from around the country to Washington, D.
/PRNewswire/ -- Ethicon Endo-Surgery, Inc. (EES) today launched the first comprehensive solution for laparoscopic sleeve gastrectomy designed to help minimize leaks, the company announced. The EES Sleeve Solution provides surgeons with cutting-edge EES surgical devices, professional education and resources aligned with the expert consensus on Laparoscopic Sleeve Gastrectomy recently published in Surgery for Obesity and Related Diseases (SOARD).
/PRNewswire-USNewswire/ -- The 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) takes place this week at the Moscone Convention Center. Each day, the public relations department will send the most newsworthy components of the meeting. To schedule an interview about any of the topics below, contact AAOS public relations.
WHITEHOUSE STATION, N.J. (AP) — An experimental anti-clotting drug that Merck & Co. is developing increased risk of bleeding internally in a study, the second time it's shown that dangerous side effect. Merck says the top-line results from a study called TRA-2P show vorapaxar, when added to standard anticlotting therapy, reduces risk of heart attack, stroke, death from heart disease or emergency heart surgery.
/PRNewswire/ -- InspireMD, Inc., a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, announced positive clinical results from an investigator-sponsored controlled randomized trial conducted in Chile.
/PRNewswire/ -- Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer. The collaboration will explore the capabilities of Exosome RNA biofluid-based diagnostic technology for early identification, progression monitoring and disease risk stratification in glioma, the most common form of brain cancer.